Last update March 25, 2022

C21H25ClFN3O3,C6H8O7,2H2O

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Mosapride, a substituted benzamide, is a prokinetic drug that increases gastrointestinal motility and accelerates gastric emptying. Used in gastritis and gastroesophageal reflux. Oral administration.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (very high percentage of protein binding and moderately high molecular weight) make it highly unlikely that significant quantities will pass into breast milk.

No cardiac arrhythmias have been reported in patients treated with mosaprida, unlike what happens with a similar drug, cisapride. (Tack 2012, Cho 2004, Endo 2002)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.


See below the information of this related product:

  • Cisapride (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Omeprazole ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C21H25ClFN3O3,C6H8O7,2H2O is Mosapride Citrate in Molecular formula.

Is written in other languages:

C21H25ClFN3O3,C6H8O7,2H2O is also known as

Group

C21H25ClFN3O3,C6H8O7,2H2O belongs to this group or family:

Tradenames

Main tradenames from several countries containing C21H25ClFN3O3,C6H8O7,2H2O in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 650 daltons
Protein Binding 99 %
pKa 14.46 -
Tmax 0.8 ± 0.1 hours
2.4 hours

References

  1. Camarillo Cárdenas KP, García González J, Argüelles Tello FA, Ocampo Ramírez JA, Moreno Hernández JB, Pendela MM. Relative bioavailability and pharmacokinetic comparison of a fixed-dose combination tablet of mosapride, pancreatin, and simethicone relative to single-component mosapride tablets in healthy Mexican subjects. Fundam Clin Pharmacol. 2022 Apr;36(2):427-435. Consulted on March 25, 2022 Abstract
  2. MIMS. Mosapride (Gasmotin). Internet. 2022 Consulted on March 25, 2022 Full text (link to original source)
  3. Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, Müller-Lissner S, Quigley EM, Schuurkes J, De Maeyer JH, Stanghellini V. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67. Abstract
  4. Kim SH, Park YS, Kim JM, Park HJ, Lee MH, Park HK, Kim YJ, Cho SH, Shaw LM, Kang JS. Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. Int J Clin Pharmacol Ther. 2012 Jul;50(7):524-31. Abstract
  5. Huang J, Tian Y, Zhang ZJ, Li J, Cao X. Pharmacokinetics and bioequivalence study of two mosapride citrate formulations after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung. 2011;61(3):167-72. Abstract
  6. Cho YK, Choi MG, Kim SH, Lee IS, Kim SW, Chung IS, Lee SY, Choi SC, Seol SY. [The effect of mosapride on quality of life in functional dyspepsia]. Korean J Gastroenterol. 2004 Mar;43(3):160-7. Korean. Abstract
  7. Endo J, Nomura M, Morishita S, Uemura N, Inoue S, Kishi S, Kawaguchi R, Iga A, Ito S, Nakaya Y. Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography. J Gastroenterol. 2002;37(11):888-95. Abstract
  8. Sakashita M, Yamaguchi T, Miyazaki H, Sekine Y, Nomiyama T, Tanaka S, Miwa T, Harasawa S. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung. 1993 Aug;43(8):867-72. Abstract

Total visits

355

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM